Bayer Pharma Aktiengesellschaft

Bayer Schering Pharma Ag

Bayer Aktiengesellschaft

Bayer Intellectual Property Gmbh

The Broad Institute, Inc.

Antonius Ter Laak

Nico Bräuer

Ulrike Röhn

Hans Briem

Wolfgang Schwede

Bernd Buchmann

Benjamin Bader

Karl-Heinz Thierauch

Andrea Rotgeri

Anne Mengel

Georg Kettschau

Clara Christ

Hermann Kuenzer

Bernhard Lindenthal

Philip Lienau

Markus Berger

Ludwig Zorn

Kai Thede

Joachim Kuhnke

Norbert Schmees

Marcus Koppitz

Roland Neuhaus

Ursula Mönning

Holger Steuber

Thomas Brumby

Peter Serno

Ingo Hartung

Jens Nagel

Steven James Ferrara

Amaury Ernesto Fernandez-Montalvan

Didier Roche

Olaf Peters

Olaf Panknin

Roman Hillig

Horst Irlbacher

Hana Cernecka

Naomi Barak

Matyas Gorjanacz

Manfred Husemann

Stuart Ince

Holger Siebeneicher

Detlef Stöckigt

Stefan Kaulfuss

Ulrike Fuhrmann

Thorsten Blume

Stephan Siegel

Stefan Nikolaus Gradl

Timo Stellfeld

Ursula Moenning

Dieter Zopf

Reinhard Nubbemeyer

Simon Anthony Herbert

Ildiko Terebesi

Antje Rottmann

Jan Hübner

Daniel Korr

Andreas Sutter

Jörg Weiske

Carlo Stresemann

Vera Pütter

Martina Schaefer

Michaele Peters

Vincent Rodeschini

Arndt Schmitz

Andrea Wagenfeld

Gernot Langer

Volker Badock

Jeffrey Stuart Mowat

Silke Köhr

Hermann Künzer

Léa Aurelie Bouché

Ernesto Amaury Fernandez-Montalvan

Stefan Niklaus Gradl

Craig Strathdee

Jacob Jaffe

Rosemary Helen Crampton

Ian Stefanuti

Katrin Nowak-reppel

Frank Sacher

Nicole Schmidt

Sabine Pilari

Amaury Ernesto Fernandez-montalvan

Jörg Wichard

Robin Meier

Nico Brauer

Ondozabal Hideki Miyatake

Léa Bouche

Emesto Amaury Fernandez-Montalvan

Jacob D Jaffe

Naomi Barack

The present invention provides acyl sulfonamide compounds of general formula (I):

Acyl sulfonamides for treating cancer

The present invention covers 4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-7-carboxamide compounds of general formula (I): in which R, R, R, R, R, R, R, R, Rand X are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer, as a sole agent or in combination with other active ingredients. 

4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-7-carboxamides

The invention relates to furane derivatives of formula (I) as inhibitors of ATAD2, a process for their preparation and use thereof. 

Furane derivatives as inhibitors of ATAD2

The present invention covers [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanone compounds of general formula (I): in which R, R, R, Rand Rare as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of disorders, in particular of gynecological disorders, hyperproliferative disorders, metabolic disorders, or inflammatory disorders as a sole agent or in combination with other active ingredients.

[8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones

The present invention relates to protein-lysine N-methyltransferase SMYD2 (SET and MYND domain-containing protein 2) inhibitors, in particular SMYD2-inhibitory substituted cyanoguanidine-pyrazolines of general formula (I) wherein R, R, R, R, R, X and r have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyper-proliferative disorders, in particular for cancer, respectively tumor disorders. The present invention furthermore relates to the use of SMYD2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility. 

Aryl-cyanoguanidine compounds

The present invention relates to novel benzimidazole derivatives of the general formula processes for their preparation and their use for the production of pharmaceutical compositions for the treatment of diseases and indications that are connected with the receptor EP4.

Benzimidazole derivatives as EP4 antagonists

The invention relates to a pharmaceutical composition for non-hormonal, on-demand contraception and to processes for preparing this pharmaceutical composition. The latter comprises 2H-indazole as novel EP2 receptor antagonists in combination with COX inhibitors. The invention furthermore provides a method for non-hormonal female-controlled on-demand contraception where a pharmaceutical composition comprising EP2 receptor antagonists in combination with COX inhibitors is taken on demand prior to expected sexual intercourse.

Pharmaceutical composition and the use thereof, and application regime of said pharmaceutical composition for on-demand contraception

The present invention relates to novel 2H-indazoles of the general formula (I), methods for the preparation thereof and the use thereof for the production of pharmaceutical agents for the treatment of diseases and indications which are linked with the EP-receptor. 

[object Object]

This invention relates to compounds of general formula I in which Rand Rare described in this application, the use of the compounds of general formula I as inhibitors of protein tyrosine kinases for treatment of various diseases as well as the compounds of general formulas II and III as intermediate compounds for the production of compounds of general formula I, wherein X, Rand Rhave the meaning that is described in general formulas II and III.

3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents

The invention relates to pyrazolopyridines according to the general formula (I): and salts thereof, to pharmaceutical compositions comprising said pyrazolopyridines and to a method of preparing said pyrazolopyridines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with angiopoietin and therefore influence Tie2 signalling.

Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same

The invention relates to substituted arylpyrazolopyridines according to the general formula (I): in which A, B, D, E, R, R, R, R, R, Rand q are as defined in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted arylpyrazolopyridines, to methods of preparing said substituted arylpyrazolopyridines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.

Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same

Growing community of inventors

Berlin, Germany

Antonius Ter Laak